Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
Szu-Chun YangWu-Wei LaiJason C HsuWu-Chou SuJung-Der WangPublished in: PloS one (2020)
Erlotinib appeared to be cost-effective. Lifetime psychometric scores may provide additional information for effectiveness evaluation.